Please upgrade your browser.
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset.
OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy.
Presentations from the 12 International Kidney Cancer Symposium, held in October 2013, at Chicago, Illinois, USA.
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
CELLDEX THERAPEUTICS INC Symbol U : CLDX Recent Sedar Documents Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity
Very favorable safety profile; no evidence of immune related toxicities; three patients with significant tumor shrinkage...
Virginia Beach was notified by their insurance provider that their plan no longer qualified under Obamacare’s regulations.
Pastor Joey Butler, the beloved Blue Springs minister whose faith inspired thousands, has died at age 51. Suffering with renal cell cancer...
"They don't want a cure."
A new and independent analysis of Obamacare warns of a ticking time bomb...
A clinical, radiologic, and pathologic study of 34 cases.
|Powered by NeonCRM|